A phase I trial of sequential administration of Triapine (3-aminopyridine-2-carboxaldehyde) [OCX 0191] followed by fludarabine in adults with relapsed and refractory leukemias and myelodysplasias.

Trial Profile

A phase I trial of sequential administration of Triapine (3-aminopyridine-2-carboxaldehyde) [OCX 0191] followed by fludarabine in adults with relapsed and refractory leukemias and myelodysplasias.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2010

At a glance

  • Drugs Fludarabine; OCX 191
  • Indications Leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top